Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Following a fantastic event, Theolytics was announced the winner of the BioEscalator’s inaugural Pitch Finale, which was kindly supported by Santander Universities UK.

Following on from the success of our Pitch Battle in April, we sought to encourage the peer mentorship within our community. As the BioEscalator ecosystem currently comprises 13 high-growth companies in the early funding stages of seed to post series A, we were keen to utilise this wealth of knowledge and experience to support our companies in the process of raising series A, by matching our top start-ups with mentors from within our company pool. After 3 weeks of training and feedback on their business plans and investor slide decks, Theolytics, who are developing oncolytic viruses as therapeutics, Alchemab Therapeutics, who are utilising native antibodies and a novel platform to discover new therapeutics and Bioarchitech, who are developing novel oncolytic viral therapies, all gave excellent 6 minute pitches to our esteemed judging panel.

The full story is available on the BioEscalator website

Similar stories

Long COVID: vaccination could reduce symptoms, new research suggests

While evidence suggests that people who are vaccinated before they get COVID are less likely to develop long COVID than unvaccinated people, the effectiveness of vaccination on existing long COVID has been less clear.

Com-COV vaccine study to research third dose booster options for 12-to-15-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a further study of COVID-19 vaccination schedules in young people aged 12 to 15 – with a focus on assessing different options for a third dose booster vaccination.

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.